AbbVie files fast-acting Botox successor in US

AbbVie is hoping to extend its range of neurotoxin-based pharma and cosmetic products with a short-acting successor to its blockbuster Botox brand.

Ipsen’s John Chaddock on making neurotoxins a priority for h...

Injected neurotoxins can be incredibly potent in treating spasticity from neurological diseases, but the field doesn’t always get the attention it needs.  Ipsen’s John Chaddock tells u

Allergan gets FDA okay for paediatric Botox use

Allergan abandons women’s health sale plan as profit slumps

Shares in Allergan fell after the company said it had swung to a loss in the last quarter of 2018, and forecast 2019 revenues below analyst expectations.

Allergan buys Bonti and its Botox successor, as biosimilar l...

Allergan has bought the privately-held biotech Bonti, which has been developing a fast-acting, short duration replacement alternative to Botox ahead of potentially che